{
    "organizations": [],
    "uuid": "4d1bf100b5253de91342f340de15544e9e5ff45c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vistagen-therapeutics-initiates-ph/brief-vistagen-therapeutics-initiates-phase-2-study-of-av-101-for-major-depressive-disorder-idUSFWN1RI0EW",
    "ord_in_thread": 0,
    "title": "BRIEF-Vistagen Therapeutics Initiates Phase 2 Study Of AV 101 For Major Depressive Disorder",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 5 (Reuters) - VistaGen Therapeutics Inc:\n* 101 FOR MAJOR DEPRESSIVE DISORDER * LINE RESULTS FROM ELEVATE ARE EXPECTED IN FIRST HALF OF 2019 â€‹ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-05T20:13:00.000+03:00",
    "crawled": "2018-04-06T21:55:20.019+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "vistagen",
        "therapeutic",
        "inc",
        "major",
        "depressive",
        "disorder",
        "line",
        "result",
        "elevate",
        "expected",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}